Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jack M. Anthony | M | - |
Osprey Pharmaceuticals Ltd.
 Osprey Pharmaceuticals Ltd. Pharmaceuticals: GenericHealth Technology Osprey Pharmaceuticals Ltd. develops a series of proprietary therapeutic drugs. Osprey Pharmaceuticals is developing a unique family of therapeutic proteins capable of treating chronic diseases. Osprey's broad technology platform is based on the critical insight that many common diseases are propagated by overabundant and overactive leukocytes. The Company's patented Leukocyte Population Modulators (LPMs) selectively and systematically remove these disease-related leukocytes by targeting the chemokine system a complex network of small proteins and their receptors that regulate the movement and activity of leukocytes. The Company's lead compound is in early clinical development for the treatment of diseases associated with chronic inflammation. Osprey also has a portfolio of preclinical LPMs that target a variety of diseases including inflammatory and immunological disorders, oncology, and cardiovascular disease. Osprey Pharmaceuticals was founded in 1997 and is located in Saint-Laurent, Canada. | - |
| Richard H. Irving | M | - |
The University of Manchester
| 6 years |
| Wai Ching Wong | F | 63 |
The University of Manchester
| 5 years |
| Choon Beng Ng | M | 58 |
Newcastle University
| 5 years |
| Steven Swinson | M | - |
The University of Manchester
| 4 years |
| Panos Andreas Loizou | M | 60 |
The University of Manchester
| 7 years |
| Fung Man Wai | M | 75 |
The University of Manchester
| 4 years |
| Henryk Kalisz | M | - |
The University of Manchester
| 8 years |
| John R. Mcdonald | M | - |
Osprey Pharmaceuticals Ltd.
Osprey Pharmaceuticals Ltd. Pharmaceuticals: GenericHealth Technology Osprey Pharmaceuticals Ltd. develops a series of proprietary therapeutic drugs. Osprey Pharmaceuticals is developing a unique family of therapeutic proteins capable of treating chronic diseases. Osprey's broad technology platform is based on the critical insight that many common diseases are propagated by overabundant and overactive leukocytes. The Company's patented Leukocyte Population Modulators (LPMs) selectively and systematically remove these disease-related leukocytes by targeting the chemokine system a complex network of small proteins and their receptors that regulate the movement and activity of leukocytes. The Company's lead compound is in early clinical development for the treatment of diseases associated with chronic inflammation. Osprey also has a portfolio of preclinical LPMs that target a variety of diseases including inflammatory and immunological disorders, oncology, and cardiovascular disease. Osprey Pharmaceuticals was founded in 1997 and is located in Saint-Laurent, Canada. | 14 years |
| Michael Steward | M | - |
Newcastle University
| 6 years |
| Roger Aston | M | 68 |
The University of Manchester
| 6 years |
| Stewart Craig | M | 63 |
Newcastle University
| 7 years |
| Tony Bruno | M | 62 |
The University of Manchester
| 4 years |
| David Poulter | M | 62 |
The University of Manchester
| 3 years |
| Kwok Wah Tam | M | 74 |
The University of Manchester
| 1 years |
| Mark Irwin | M | 59 |
The University of Manchester
| 4 years |
| Ashavani Kumar Mohindra | M | - |
The University of Manchester
| 4 years |
| Steven Mann | M | - |
The University of Manchester
| 3 years |
| Roger Howard Mitchell | M | 82 |
The University of Manchester
| 3 years |
| William Armstrong | M | - |
Newcastle University
| 4 years |
| Ioannis Panagiotis Lioupis | M | 65 |
Newcastle University
| 4 years |
| Spiros Jamas | M | 63 |
The University of Manchester
| 4 years |
| Okechukwu John Mbonu | M | 71 |
The University of Manchester
| 3 years |
| Chun Kooi Ng | M | 63 |
The University of Manchester
| 4 years |
| See Wai Ng | F | 61 |
The University of Manchester
| 4 years |
| Richard Damien Glasspool | M | 68 |
The University of Manchester
| 4 years |
| Sjoerd Wadman | M | - |
The University of Manchester
| 3 years |
| Cheng Seong Yeoh | M | 61 |
The University of Manchester
| 4 years |
| Amir Tavakkol | M | 69 |
The University of Manchester
| 3 years |
| Malcolm France | M | - |
The University of Manchester
| 4 years |
| Shu Min Pang | M | 65 |
The University of Manchester
| 4 years |
| Beverley June Hughes | F | 74 |
The University of Manchester
| 1 years |
| Zhi Guo Su | M | 70 |
The University of Manchester
| 3 years |
| Zahi Labib Jaris Musallam | M | 68 |
The University of Manchester
| 1 years |
| Ede Dafinone | M | - |
The University of Manchester
| 4 years |
| Mario Reis | M | 64 |
The University of Manchester
| 4 years |
| Wai Hong Choi | M | 66 |
The University of Manchester
| 4 years |
| Nassim Usman | M | 64 |
Osprey Pharmaceuticals Ltd.
Osprey Pharmaceuticals Ltd. Pharmaceuticals: GenericHealth Technology Osprey Pharmaceuticals Ltd. develops a series of proprietary therapeutic drugs. Osprey Pharmaceuticals is developing a unique family of therapeutic proteins capable of treating chronic diseases. Osprey's broad technology platform is based on the critical insight that many common diseases are propagated by overabundant and overactive leukocytes. The Company's patented Leukocyte Population Modulators (LPMs) selectively and systematically remove these disease-related leukocytes by targeting the chemokine system a complex network of small proteins and their receptors that regulate the movement and activity of leukocytes. The Company's lead compound is in early clinical development for the treatment of diseases associated with chronic inflammation. Osprey also has a portfolio of preclinical LPMs that target a variety of diseases including inflammatory and immunological disorders, oncology, and cardiovascular disease. Osprey Pharmaceuticals was founded in 1997 and is located in Saint-Laurent, Canada. | - |
| Neoclis Nicolaou | M | 64 |
The University of Manchester
| 4 years |
| Kwai Wing Lai | M | 62 |
The University of Manchester
| 4 years |
| Wai Sheun Choy | F | 60 |
Newcastle University
| 4 years |
| Tay Hock Lau | M | 65 |
The University of Manchester
| 4 years |
| Paddy Padmanathan | M | 66 |
The University of Manchester
| 4 years |
| Giles Dacre Marshall | M | - |
The University of Manchester
| 4 years |
| Richard Fraser-Smith | M | 60 |
The University of Manchester
| 4 years |
| Valerie Smart | F | - |
The University of Manchester
| 4 years |
| Mark Portelli | M | - |
The University of Manchester
| 4 years |
| Vatche George Artin Dakisian | M | 67 |
The University of Manchester
| 1 years |
| William Lam | M | 65 |
The University of Manchester
| 4 years |
| Yemisi Ayeni | F | - |
The University of Manchester
| 4 years |
| Wai Ming Ng | M | 64 |
The University of Manchester
| 4 years |
| Anthony Paul | M | - |
Newcastle University
| 4 years |
| Yat-Ming Lam | M | 64 |
Newcastle University
| 4 years |
| Che Yin Tang | M | 68 |
The University of Manchester
| 1 years |
| Somchai Boonnamsiri | M | 69 |
The University of Manchester
| 1 years |
| Miloud Bekkoucha | M | - |
The University of Manchester
| 1 years |
| Fernando Augusto Rojas Pinto | M | 69 |
The University of Manchester
| 1 years |
| Paul Glover | M | - |
Newcastle University
| 1 years |
| Donald Ncube | M | 76 |
The University of Manchester
| 2 years |
| Cheung Shing Ng | M | 62 |
The University of Manchester
| 4 years |
| Hany El Kafrawy | M | - |
The University of Manchester
| 4 years |
| Chong Keat Chew | M | 63 |
The University of Manchester
| 4 years |
| Seong Liam Gan | M | 68 |
The University of Manchester
| 4 years |
| Rolf Andreas Wikborg | M | 66 |
The University of Manchester
| 4 years |
| Siew Cheong Ho | M | 61 |
Newcastle University
| 4 years |
| Robert Parkinson | M | 65 |
The University of Manchester
| 4 years |
| Barbara Finck | M | 77 |
Osprey Pharmaceuticals Ltd.
Osprey Pharmaceuticals Ltd. Pharmaceuticals: GenericHealth Technology Osprey Pharmaceuticals Ltd. develops a series of proprietary therapeutic drugs. Osprey Pharmaceuticals is developing a unique family of therapeutic proteins capable of treating chronic diseases. Osprey's broad technology platform is based on the critical insight that many common diseases are propagated by overabundant and overactive leukocytes. The Company's patented Leukocyte Population Modulators (LPMs) selectively and systematically remove these disease-related leukocytes by targeting the chemokine system a complex network of small proteins and their receptors that regulate the movement and activity of leukocytes. The Company's lead compound is in early clinical development for the treatment of diseases associated with chronic inflammation. Osprey also has a portfolio of preclinical LPMs that target a variety of diseases including inflammatory and immunological disorders, oncology, and cardiovascular disease. Osprey Pharmaceuticals was founded in 1997 and is located in Saint-Laurent, Canada. | 3 years |
| Michael John McGhee | M | 68 |
The University of Manchester
| 3 years |
| Bien Chuan Tan | M | 68 |
The University of Manchester
| 3 years |
| Gregory McMahon | M | 64 |
The University of Manchester
| 4 years |
| Andrew Leigh Bryant | M | 67 |
The University of Manchester
| 4 years |
| Timothy Pennington | M | 63 |
The University of Manchester
| 3 years |
| Jonathan Nicholls | M | 67 |
The University of Manchester
| 3 years |
| Paul de Rome | M | 66 |
The University of Manchester
| 3 years |
| Michael Stewart Levy | M | 61 |
The University of Manchester
| 4 years |
| Ian Bennett | M | - |
The University of Manchester
| 4 years |
| Khalid Al-Faddagh | M | 69 |
The University of Manchester
| 1 years |
| Seow Kee Fong | M | 67 |
The University of Manchester
| 4 years |
| Helen Walsh | F | - |
The University of Manchester
| 3 years |
| Ian Thomas Birks | M | 65 |
The University of Manchester
| 4 years |
| Wing Nang Chan | M | 63 |
Newcastle University
| 4 years |
| Yew Hiap Koh | M | - |
The University of Manchester
| 4 years |
| Ahmad Ruslan Zahari bin Zakaria | M | 63 |
Newcastle University
| 4 years |
| Mohamad Khir bin Harun | M | 74 |
The University of Manchester
| 3 years |
| Webster Dunbar | M | 62 |
The University of Manchester
| 4 years |
| Colin Barrow | M | - |
The University of Manchester
| 4 years |
| Rami Waleed Kamel Hamdallah | M | 65 |
The University of Manchester
| 1 years |
| Tony Starling | M | - |
Newcastle University
| 4 years |
| Chi Ming Lam | M | 65 |
The University of Manchester
| 4 years |
| Jeremy Chan | M | - |
The University of Manchester
| 4 years |
| Jane Louise Crawford | F | 67 |
The University of Manchester
| 3 years |
| Hongsheng Su | M | - |
Osprey Pharmaceuticals Ltd.
Osprey Pharmaceuticals Ltd. Pharmaceuticals: GenericHealth Technology Osprey Pharmaceuticals Ltd. develops a series of proprietary therapeutic drugs. Osprey Pharmaceuticals is developing a unique family of therapeutic proteins capable of treating chronic diseases. Osprey's broad technology platform is based on the critical insight that many common diseases are propagated by overabundant and overactive leukocytes. The Company's patented Leukocyte Population Modulators (LPMs) selectively and systematically remove these disease-related leukocytes by targeting the chemokine system a complex network of small proteins and their receptors that regulate the movement and activity of leukocytes. The Company's lead compound is in early clinical development for the treatment of diseases associated with chronic inflammation. Osprey also has a portfolio of preclinical LPMs that target a variety of diseases including inflammatory and immunological disorders, oncology, and cardiovascular disease. Osprey Pharmaceuticals was founded in 1997 and is located in Saint-Laurent, Canada. | - |
| Robert Wagstaff | M | - |
Osprey Pharmaceuticals Ltd.
Osprey Pharmaceuticals Ltd. Pharmaceuticals: GenericHealth Technology Osprey Pharmaceuticals Ltd. develops a series of proprietary therapeutic drugs. Osprey Pharmaceuticals is developing a unique family of therapeutic proteins capable of treating chronic diseases. Osprey's broad technology platform is based on the critical insight that many common diseases are propagated by overabundant and overactive leukocytes. The Company's patented Leukocyte Population Modulators (LPMs) selectively and systematically remove these disease-related leukocytes by targeting the chemokine system a complex network of small proteins and their receptors that regulate the movement and activity of leukocytes. The Company's lead compound is in early clinical development for the treatment of diseases associated with chronic inflammation. Osprey also has a portfolio of preclinical LPMs that target a variety of diseases including inflammatory and immunological disorders, oncology, and cardiovascular disease. Osprey Pharmaceuticals was founded in 1997 and is located in Saint-Laurent, Canada. | - |
| Nigel Crockett | M | 59 |
The University of Manchester
| 4 years |
| Alan Butcher | M | - |
The University of Manchester
| 3 years |
| Richard McGaw | M | - |
The University of Manchester
| 3 years |
| Trevor Civval | M | - |
The University of Manchester
| 4 years |
| Ashleigh Palmer | M | 61 |
The University of Manchester
| 3 years |
| George Sebastian Matthew Bullto | M | 64 |
The University of Manchester
| 4 years |
| Sui See Yuen | M | 73 |
The University of Manchester
| 1 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United Kingdom | 94 | 94.00% |
| Canada | 6 | 6.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Philip J. Coggins
- Personal Network
